(19)
(11) EP 1 212 081 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.12.2005 Bulletin 2005/52

(45) Mention of the grant of the patent:
26.10.2005 Bulletin 2005/43

(21) Application number: 00965898.0

(22) Date of filing: 25.08.2000
(51) International Patent Classification (IPC)7A61K 38/55, A61K 31/00, A61K 31/4184, A61P 9/04, A61P 9/10, A61P 3/10
(86) International application number:
PCT/EP2000/008341
(87) International publication number:
WO 2001/015673 (08.03.2001 Gazette 2001/10)

(54)

USE OF ACE INHIBITORS IN THE PREVENTION OF CONGESTIVE HEART FAILURE

VERWENDUNG VON ACE INHIBITOREN ZUR PROPHYLAXE VON KONGESTIVEM HERZVERSAGEN

UTILISATIONS DES INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE POUR PREVENIR L'INSUFFISANCE CARDIAQUE GLOBALE


(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 27.08.1999 SE 9903028

(43) Date of publication of application:
12.06.2002 Bulletin 2002/24

(60) Divisional application:
04006330.7 / 1437131

(73) Proprietor: Sanofi-Aventis Deutschland GmbH
65929 Frankfurt am Main (DE)

(72) Inventors:
  • SCHOELKENS, Bernward
    65779 Kelkheim (DE)
  • BENDER, Norbert
    65719 Hofheim (DE)
  • RANGOONWALA, Badrudin
    65719 Hofheim (DE)
  • DAGENAIS, Gilles
    Quebec, J7A 3P8 (CA)
  • GERSTEIN, Hertzel
    Hamilton, Ontario L8S 4A8 (CA)
  • LJUNGGREN, Anders
    S-431 63 Mölndal (SE)
  • YUSUF, Salim
    Carlisle, Ontario L0R 1H2 (CA)


(56) References cited: : 
EP-A- 0 241 201
EP-A- 0 426 066
EP-A- 0 540 209
EP-A- 0 795 327
WO-A-00/71751
WO-A-93/20839
WO-A-97/27745
WO-A-98/30216
WO-A-99/44590
DE-A- 19 913 528
US-A- 5 190 970
US-A- 5 308 846
EP-A- 0 331 014
EP-A- 0 474 438
EP-A- 0 747 050
WO-A-00/02543
WO-A-01/15674
WO-A-96/24373
WO-A-97/49392
WO-A-99/20260
DE-A- 4 308 504
GB-A- 2 308 064
US-A- 5 266 583
US-A- 5 506 361
   
  • DATABASE WPI Week 199944 Derwent Publications Ltd., London, GB; AN 1999-520858 XP002166044 MASUDA YOSHINOBU, HONDA YAYOI, MINATO HISAO: "Inhibitor of cerebral vasospasm" & JP 11 222439 A (DAINIPPON PHARM CO LTD), 17 August 1999 (1999-08-17)
  • OGIKU N ET AL: "Prophylactic effect of imidapril on stroke in stroke -prone spontaneously hypertensive rats." STROKE, (1993 FEB) 24 (2) 245-52., XP000997781
  • STIER C T JR ET AL: "ENALAPRIL PREVENTS STROKE AND KIDNEY DYSFUNCTION IN SALT-LOADED STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS" HYPERTENSION (DALLAS), vol. 13, no. 2, 1989, pages 115-121, XP000997775 ISSN: 0194-911X
  • ROBERT MKW LEE, HONG WANG, JOHN S SMEDA: "Effects of perindopril on hypertension and stroke prevention in experimental animals" CAN. J. CARDIOL., vol. 10, no. Suppl D, November 1994 (1994-11), pages 33D-36D, XP000998206
  • J.E.F. REYNOLDS: "Martindale The Extra Pharmacopoeia" 1996 , ROYAL PHARMACEUTICAL SOCIETY , LONDON XP002166043 page 863, column 2 -page 864, column 2 page 899, column 3 -page 900, column 1 page 940, column 3 -page 941, column 1
  • EBERHARDT ROBERT T ET AL: "Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotherapy." JOURNAL OF CLINICAL PHARMACOLOGY, vol. 33, no. 11, 1993, pages 1023-1038, XP001019614 ISSN: 0091-2700
  • STIER CHARLES T JR ET AL: "Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats." JOURNAL OF HYPERTENSION, vol. 11, no. SUPPL. 3, 1993, pages S37-S42, XP001019687 Meeting on Losartan: An Orally Active Angiotensin II Antagonist;St. Paul de Vence, France; June 26-27, 1992 ISSN: 0263-6352
  • BLUMENTHAL MEL: "Treatment of congestive heart failure: Experience with fosinopril." AMERICAN JOURNAL OF HYPERTENSION, vol. 10, no. 10 PART 2, 1997, pages 289S-298S, XP001019673 ISSN: 0895-7061
  • NAKAMURA FUMIAKI ET AL: "Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters." AMERICAN JOURNAL OF PHYSIOLOGY, vol. 267, no. 6 PART 2, 1994, pages H2297-H2304, XP001019610 ISSN: 0002-9513
  • K. PARFITT: "Martindale - The complete drug reference - Thirty-second Edition" 1999 , PHARMACEUTICAL PRESS , LONDON UK XP002176301 page 836, column 1 page 865, column 3 page 891, column 3 -page 892, column 1 page 899, column 1 page 951, column 3 page 960, column 2 -column 3
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).